Evidence map›Paper›PMID 36172729›Full record

ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2022

Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations.

Guowei Zhang, Ruirui Cheng, Yuanyuan Niu, Huijuan Wang, Xiangtao Yan, Mina Zhang, Xiaojuan Zhang, Jinpo Yang, Chunhua Wei, Zhiyong Ma

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Guowei ZhangDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Ruirui ChengDepartment of Respiratory Medicine, 
The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Yuanyuan NiuDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Huijuan WangDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Xiangtao YanDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Mina ZhangDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Xiaojuan ZhangDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Jinpo YangDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Chunhua WeiDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
Zhiyong MaDepartment of Internal Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China.
First Affiliated Hospital of Zhengzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEpidermal growth factor receptor (EGFR) mutations are often associated with non-EGFR genetic alterations, which may be a reason for the poor efficacy of EGFR tyrosine kinase inhibitors (TKIs). Here we conducted this study to explore whether EGFR-TKIs combined with chemotherapy would benefit advanced lung adenocarcinoma patients with both sensitive EGFR mutation and concomitant non-EGFR genetic alterations.

methodsCases of advanced lung adenocarcinoma with EGFR mutation combined with concomitant non-EGFR genetic alterations were retrospectively collected. And the patients were required to receive first-line EGFR-TKIs and chemotherapy combination or EGFR-TKIs monotherapy. Demographic, clinical and pathological data were collected, and the electronic imaging data were retrieved to evaluate the efficacy and time of disease progression. Survival data were obtained through face-to-face or telephone follow-up. The differences between the two groups in objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) were investigated.

results107 patients were included, including 63 cases in the combination group and 44 cases in the monotherapy group. The ORR were 78% and 50% (P=0.003), and DCR were 97% and 77% (P=0.002), respectively. At a median follow-up of 13.7 mon, a PFS event occurred in 38.1% and 81.8% of patients in the two groups, with median PFS of 18.8 mon and 5.3 mon, respectively (P<0.000,1). Median OS was unreached in the combination group, and 27.8 mon in the monotherapy group (P=0.31). According to the Cox multivariate regression analysis, combination therapy was an independent prognostic factor of PFS

conclusionsIn patients with EGFR-mutant advanced lung adenocarcinoma with concomitant non-EGFR genetic alterations, combination of TKIs and chemotherapy was significantly superior to EGFR-TKIs monotherapy, which should be the preferred treatment option.

Indexed as

Adenocarcinoma of LungLung NeoplasmsErbB ReceptorsHumansMutationProtein Kinase InhibitorsRetrospective StudiesEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsChemotherapyConcomitant genetic alterationEGFR mutationLung neoplasmsTargeted therapy

Identifiers

PMID36172729
PMCPMC9549422
OpenAlexW4298088955

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.